Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Rogaratinib in Healthy Male Subjects
NCT03484585Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rogaratinib in urothelial carcinoma (UC) and solid tumor, sponsored by Bayer. Primary endpoints: Maximum observed drug concentration in plasma (Rogaratinib), Area under the concentration-time curve from time 0 to the last measurable concentration (Rogaratinib) and 6 more. Started Apr 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT03484585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484585.